SCHEMBL22992440

SCHEMBL22992440

Cc1cn(C2CC(O)CO2)c(=O)nc1NC(=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 1/20 0.42
▸ RIN1 Q13671 1/20 0.42
▸ POLB P06746 2/20 0.38
▸ CYP2C9 P11712 2/20 0.37
▸ ADORA3 P0DMS8 4/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ P2RX3 P56373 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TMIGD3 P0DMS9 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ ADORA1 P30542 2/20 0.35
▸ ADORA2A P29274 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25504696 0.80 POLB (0.46) ABL1RIN1POLB
SCHEMBL6466613 0.80 POLB (0.52) ABL1RIN1POLB
SCHEMBL21886710 0.80 POLB (0.52) ABL1RIN1POLB
SCHEMBL25512274 0.80 POLB (0.42) ABL1RIN1POLBP2RX3TMIGD3
SCHEMBL5953531 0.80 POLB (0.52) ABL1RIN1POLB
SCHEMBL26455112 0.79 ABL1 (0.40) ABL1RIN1POLBCYP2C9ADORA3
SCHEMBL26455083 0.79 ABL1 (0.42) ABL1RIN1POLBCYP2C9ADORA3
SCHEMBL25504697 0.78 POLB (0.46) ABL1RIN1POLBCYP2C9MAPT
SCHEMBL769771 0.78 ABL1 (0.38) ABL1RIN1POLBCYP2C9ADORA3
SCHEMBL769394 0.76 ABL1 (0.38) ABL1RIN1POLBCYP2C9ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021030763-A1 MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2021-02-18 — — WO disclosed
Send feedback